Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Agendia, a molecular cancer diagnostics company, has launched TargetPrint, a new diagnostic test that allows physicians to quantitatively determine the gene expression levels of the estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 in breast cancer tumor biopsies.
Subscribe to our email newsletter
According to the company, the accurate measurement of these receptors is of paramount importance in planning treatment of breast cancer patients after surgery and assists physicians and patients in making informed treatment decisions. TargetPrint runs on Agendia’s new high density chip, which has earlier received market clearance from the FDA.
Bernhard Sixt, president and CEO of Agendia, said: “Currently available targeted therapies, such as hormone treatments, can have a huge impact on the survival and quality of life of a significant number of breast cancer patients. TargetPrint will play a key role in defining which patients are most likely to benefit from these treatments.”